Literature DB >> 2827876

Recommendations for preventing transmission of HIV in health care settings.

.   

Abstract

Mesh:

Year:  1988        PMID: 2827876      PMCID: PMC1267581     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  10 in total

1.  Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.

Authors:  L Resnick; K Veren; S Z Salahuddin; S Tondreau; P D Markham
Journal:  JAMA       Date:  1986-04-11       Impact factor: 56.272

2.  Disinfection and inactivation of the human T lymphotropic virus type III/Lymphadenopathy-associated virus.

Authors:  L S Martin; J S McDougal; S L Loskoski
Journal:  J Infect Dis       Date:  1985-08       Impact factor: 5.226

3.  Transmission of HBV from dental personnel to patients.

Authors:  M A Kane; L A Lettau
Journal:  J Am Dent Assoc       Date:  1985-04       Impact factor: 3.634

4.  Inactivation of lymphadenopathy associated virus by chemical disinfectants.

Authors:  B Spire; F Barré-Sinoussi; L Montagnier; J C Chermann
Journal:  Lancet       Date:  1984-10-20       Impact factor: 79.321

5.  Guideline for infection control in hospital personnel.

Authors:  W W Williams
Journal:  Infect Control       Date:  1983 Jul-Aug

6.  Guideline for isolation precautions in hospitals.

Authors:  J S Garner; B P Simmons
Journal:  Infect Control       Date:  1983 Jul-Aug

7.  Transmission of hepatitis B with resultant restriction of surgical practice.

Authors:  L A Lettau; J D Smith; D Williams; W D Lundquist; F Cruz; R K Sikes; S C Hadler
Journal:  JAMA       Date:  1986-02-21       Impact factor: 56.272

8.  Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light.

Authors:  B Spire; D Dormont; F Barré-Sinoussi; L Montagnier; J C Chermann
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

9.  Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.

Authors:  J S McDougal; L S Martin; S P Cort; M Mozen; C M Heldebrant; B L Evatt
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

10.  Unsuspected human immunodeficiency virus in critically ill emergency patients.

Authors:  J L Baker; G D Kelen; K T Sivertson; T C Quinn
Journal:  JAMA       Date:  1987-05-15       Impact factor: 56.272

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.